title: Combination therapy with diquafosol tetrasodium and sodium hyaluronate in patients with dry eye after laser in situ keratomileusis.
abstract: OBJECTIVE
  To evaluate the possible advantages of combination therapy with diquafosol tetrasodium and sodium hyaluronate for dry eye after laser in situ keratomileusis (LASIK).
  
  
  METHODS
  Prospective randomized comparative trial.
  
  
  METHODS
  A total of 206 eyes of 105 patients who underwent LASIK were enrolled in this study. Patients were randomly assigned to 1 of 4 treatment groups according to the postoperative treatment: artificial tears, sodium hyaluronate, diquafosol tetrasodium, and a combination of hyaluronate and diquafosol. Questionnaire responses reflecting subjective dry eye symptoms, uncorrected and corrected visual acuity, functional visual acuity, manifest refraction, tear break-up time, fluorescein corneal staining, Schirmer test, and corneal sensitivity were examined before and 1 week and 1 month after LASIK.
  
  
  RESULTS
  Distance uncorrected visual acuity was significantly better in the combination group than in the hyaluronate group 1 week and 1 month after LASIK. Near uncorrected visual acuity was significantly better in the combination group than in the artificial tear and diquafosol groups 1 week and 1 month after LASIK. Distance functional visual acuity improved significantly only in the combination group 1 month after LASIK. The Schirmer value in the combination group was significantly higher than that in the hyaluronate group at 1 month after LASIK. Subjective dry eye symptoms in the combination group improved significantly compared with those in the other groups 1 week after surgery.
  
  
  CONCLUSIONS
  Our results suggest that hyaluronate and diquafosol combination therapy is beneficial for early stabilization of visual performance and improvement of subjective dry eye symptoms in patients after LASIK.
authors: Minamiaoyama Eye Clinic, Tokyo, Japan. Electronic address: ikuko@tka.att.ne.jp.
authors: Ikuko
authors: I
authors: Toda
authors: Minamiaoyama Eye Clinic, Tokyo, Japan.
authors: Takeshi
authors: T
authors: Ide
authors: Minamiaoyama Eye Clinic, Tokyo, Japan.
authors: Teruki
authors: T
authors: Fukumoto
authors: Minamiaoyama Eye Clinic, Tokyo, Japan.
authors: Yoshiyuki
authors: Y
authors: Ichihashi
authors: Keio University, School of Medicine, Tokyo, Japan.
authors: Kazuo
authors: K
authors: Tsubota
mesh_terms: D000328:Adult; D003315:Cornea / Q000502:physiology; D004359:Drug Therapy, Combination; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use*; D020731:Keratomileusis, Laser In Situ / Q000009:adverse effects*; D008297:Male; D009883:Ophthalmic Solutions; D011122:Polyphosphates / Q000627:therapeutic use*; D011446:Prospective Studies; D058912:Purinergic P2Y Receptor Agonists / Q000627:therapeutic use*; D012029:Refraction, Ocular / Q000502:physiology; D011795:Surveys and Questionnaires; D013666:Tears / Q000502:physiology; D014500:Uracil Nucleotides / Q000627:therapeutic use*; D055675:Viscosupplements / Q000627:therapeutic use*; D014792:Visual Acuity / Q000502:physiology
chemical_list: D009883:Ophthalmic Solutions; D011122:Polyphosphates; D058912:Purinergic P2Y Receptor Agonists; D014500:Uracil Nucleotides; D055675:Viscosupplements; C403315:diquafosol; D006820:Hyaluronic Acid